Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

January 3, 2014 updated by: Genta Incorporated

Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may help fludarabine and cyclophosphamide kill more cancer cells by making them more sensitive to the drugs. It is not yet known if fludarabine and cyclophosphamide are more effective with or without oblimersen.

PURPOSE: Randomized phase III trial to compare the effectiveness of fludarabine and cyclophosphamide with or without oblimersen in treating patients who have relapsed or refractory chronic lymphocytic leukemia.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

  • Compare the complete response and nodular partial response of patients with relapsed or refractory chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide with or without oblimersen.
  • Compare the overall response rate, response duration, survival, and time to progression in patients treated with these regimens.
  • Compare the clinical benefit and safety of these regimens in these patients.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to disease response to prior fludarabine-containing therapy (responsive vs refractory), number of prior regimens (1-2 vs 3 or more), and duration of response to last prior therapy (more than 6 months vs 6 months or fewer). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oblimersen IV continuously on days 1-7 via an infusion pump (ending on day 8) and fludarabine IV over 20-30 minutes and cyclophosphamide IV over 30-60 minutes on days 5-7. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 11 and continuing until blood counts recover.
  • Arm II: Patients receive fludarabine IV over 20-30 minutes followed by cyclophosphamide IV over 30-60 minutes on days 1-3. Patients also receive G-CSF SC beginning on day 7 and continuing until blood counts recover.

Treatment in both arms continues every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed at 1 month and then every 2 months for 2 years.

PROJECTED ACCRUAL: A total of 200 patients (100 per arm) will be accrued for this study within 1 year.

Study Type

Interventional

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New Jersey
      • Berkeley Heights, New Jersey, United States, 07922
        • Genta Incorporated

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

DISEASE CHARACTERISTICS:

  • Diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) requiring therapy

    • Primary resistance, defined as disease progression without response during at least 2 courses of myelosuppressive therapy OR
    • Relapsed disease, defined as a response (remission or plateau) followed by relapse on or off prior therapy
    • At least 1 prior regimen must have contained fludarabine

  • Intermediate or high-risk CLL

    • Intermediate-risk disease must satisfy at least 1 of the following criteria for active disease:

      • Massive or progressive splenomegaly and/or lymphadenopathy

        • Spleen tip greater than 6 cm below costal margin
      • More than 10% weight loss within the past 6 months
      • Grade 2 or 3 fatigue
      • Fevers greater than 100.5 degrees F or night sweats for more than 2 weeks without evidence of infection
      • Progressive lymphocytosis with an increase of more than 50% over a 2-month period or an anticipated doubling time of less than 6 months
      • Worsening anemia or thrombocytopenia

  • Measurable disease with all of the following:

    • Absolute lymphocytosis greater than 5,000/mm^3
    • Lymphocytosis of small to moderate-size lymphocytes with less than 55% prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically determined by manual differential
    • Bone marrow aspirate smear with at least 30% nucleated cells that are lymphoid or a bone marrow core biopsy showing lymphoid infiltrates compatible with CLL
    • Normocellular or hypercellular bone marrow
    • Lymphocyte immunophenotype that shows a predominant B-cell monoclonal population
  • No Rai stage 0 CLL or stable CLL not requiring therapy
  • No secondary leukemia or history of antecedent hematologic disorder prior to initial onset of CLL (e.g., myelodysplasia)

PATIENT CHARACTERISTICS:

Age:

  • Over 18

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • See Disease Characteristics
  • Platelet count at least 50,000/mm^3 (hematopoietic growth factor or transfusion independent)
  • Negative Coombs' test
  • No bleeding or coagulation disorder
  • No history of hemolytic anemia, including autoimmune hemolytic anemia
  • No history of autoimmune thrombocytopenia

Hepatic:

  • Albumin at least 3.0 g/dL
  • Bilirubin no greater than 2 mg/dL
  • AST no greater than 1.5 times upper limit of normal (ULN) (5 times ULN if due to CLL)
  • PT no greater than 1.5 times ULN OR
  • INR no greater than 1.3
  • PTT no greater than 1.5 times ULN
  • No chronic hepatitis or cirrhosis

Renal:

  • Creatinine no greater than 2.0 mg/dL

Cardiovascular:

  • No uncontrolled congestive heart failure
  • No active symptoms of coronary artery disease (i.e., uncontrolled arrhythmia or recurrent chest pain despite prophylactic medication)
  • No New York Heart Association class III or IV disease
  • No cardiovascular signs or symptoms grade 2 or greater

Other:

  • Able to maintain an ambulatory infusion pump
  • HIV negative
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • No known hypersensitivity to phosphorothioate-containing oligonucleotides, fludarabine, or cyclophosphamide
  • No concurrent medical disease that would preclude study participation
  • No uncontrolled seizure disorder
  • No unresolved serious infection
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior autologous or allogeneic stem cell transplantation
  • At least 3 weeks since prior immunologic therapy, cytokine therapy, vaccine therapy, or other biologic therapy for CLL and recovered
  • No concurrent interleukin-11

Chemotherapy:

  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy and recovered

Endocrine therapy:

  • No concurrent corticosteroid therapy

Radiotherapy:

  • At least 3 weeks since prior radiotherapy for CLL and recovered

Surgery:

  • No prior organ allograft
  • At least 3 weeks since prior major surgery for CLL and recovered

Other:

  • At least 3 weeks since other prior therapy for CLL and recovered
  • No other concurrent investigational therapy
  • No concurrent therapeutic anticoagulation
  • No concurrent immunosuppressive drugs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Masking: None (Open Label)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Genta Incorporated

Investigators

  • Study Chair: Stanley R. Frankel, MD, Genta Incorporated

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2001

Study Completion (Actual)

February 1, 2007

Study Registration Dates

First Submitted

September 13, 2001

First Submitted That Met QC Criteria

January 26, 2003

First Posted (Estimate)

January 27, 2003

Study Record Updates

Last Update Posted (Estimate)

January 6, 2014

Last Update Submitted That Met QC Criteria

January 3, 2014

Last Verified

October 1, 2003

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CDR0000068932
  • GENTA-GL303
  • UCLA-0104008

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Leukemia

Clinical Trials on cyclophosphamide

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe